Fierce Biotech5d
Unity's eye treatment fails to match Eylea, though analysts still see a path forward
Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
Fierce Biotech6d
Opthea's eye disease drug defeated by Eylea in phase 3, leaving biotech to mull future
Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...
BioSpace5d
Opthea, UNITY Fail to Unseat Regeneron’s Eylea in Vision Disorders
The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...
pharmaphorum11d
Novartis next generation eye drug outperforms Eylea
Novartis is to file its next-generation eye drug in 2018 after it won out in a head-to-head trial with Bayer/Regeneron’s rival, Eylea. Brolucizumab (RTH258) could offer a convenience advantage ...
BGR28d
Most common eye colors: What percentage of people have each one?
If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. Have you ever locked eyes with someone and wondered how rare their eye color is?
New York Post28d
Texas middle schoolers shared needle during mass classroom tattoo sessions — in front of oblivious teachers
Texas middle schoolers passed around a shared needle and participated in mass tattooing sessions in classrooms while their oblivious teachers carried on with their lessons, leaving parents ...
Business Insider16d
Eylea biosimilar injunction denial ‘negative’ for Regeneron, says UBS
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...
Investing16d
Regeneron stock dips as court denies Eylea patent stay
Investing.com -- Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell 1.5% following a U.S. appeals court decision that upheld a previous ruling, effectively denying a stay on ...
Who What Wear on MSN10d
Cancel Your Filler Appointment—This Derm-Developed Eye Cream Is Your Needle-Free Alternative
With genetics working against me, it's hard to find an eye cream that really delivers on the brightening and de-puffing side ...
New Scientist20d
'Amazing' spinning needle proof unlocks a whole new world of maths
Mathematicians have solved a decades-old problem related to spinning a needle, in what has been hailed as one of the most important mathematical results in recent times. Once seen as “impossible ...
pharmaphorum5d
Roche grabs FDA okay for would-be blockbuster eye drug faricimab
The FDA has approved Roche's much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron's market leading drug Eylea. The US regulator has ...